A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER - Concepedia

Concepedia

Publication | Open Access

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

DOI Full Paper Access

50

Citations

21

References

2020

Year

Jonathan W. Goldman, Julien Mazières, Fabrice Barlési, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff,

Frontiers in Oncology

Abstract

www.ClinicalTrials.gov, identifier: NCT02152631.

References

	Year	Citations

Page 1